Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 423

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes

Kaminskas, Edvardas, Farrell, Ann, Abraham, Sophia, Baird, Amy, Hsieh, Li-Shan, Lee, Shwu-Luan, Leighton, John K., Patel, Hasmukh, Rahman, Atiqur, Sridhara, Rajeshwara, Wang, Yong-Cheng, Pazdur, Richard·2005·Clinical Cancer Research

Abstract

Purpose: This article summarizes data submitted to the U.S. Food and Drug Administration for marketing approval of azacitidine as injectable suspension (Vidaza, Pharmion Corporation, Boulder, CO) for treatment of patients with myelodysplastic syndrome. Experimental Design: In one phase 3 controlled trial, 191 study subjects were randomized to treatment with azacitidine or to observation; an additional 120 patients were treated with azacitidine in two phase 2 single arm studies. The primary efficacy end point was the overall response rate, defined as complete or partial normalization of peripheral blood counts and bone marrow blast percentages for at least 4 weeks. Results: In the controlled trial, the overall response rate was 15.7% in the azacitidine treatment group; there were no responders in the observation group (P < 0.0001). Response rates were similar in the two single arm studies. During response patients stopped being red cell or platelet transfusion dependent. Median duration of responses was at least 9 months. An additional 19% of azacitidine-treated patients had less than partial responses, most becoming transfusion independent. The most common adverse events attributed to azacitidine were gastrointestinal, hematologic, local (injection site), and constitutional. There were no azacitidine-related deaths. Conclusions: On May 19, 2004 the U.S. Food and Drug Administration approved azacitidine as injectable suspension for treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia. Full prescribing information is available at http://www.fda.gov/cder/foi/label/2004/050794lbl.pdf. Azacitidine is the first agent approved for treatment of myelodysplastic syndrome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-04-2135

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 423

Metadata

Authors
Kaminskas, E., Farrell, A., Abraham, S., Baird, A., Hsieh, L.-S., Lee, S.-L., Leighton, J. K., Patel, H., Rahman, A., Sridhara, R., Wang, Y.-C., & Pazdur, R.
Venue
Clinical Cancer Research
Published
2005-05-15
Volume
11
Issue
10
Pages
3604-3608
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2159104864
Cited by
423
References
20
FWCI
14.28
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-2135
The paper
Kaminskas, E., Farrell, A., Abraham, S., Baird, A., Hsieh, L.-S., Lee, S.-L., Leighton, J. K., Patel, H., Rahman, A., Sridhara, R., Wang, Y.-C., & Pazdur, R. (2005). Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-2135

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.